PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy

Deep Learning Reconstruction to Improve the Quality of MR Imaging: Evaluating the Best Sequence for T-category Assessment in Non-small Cell Lung Cancer Patients

PURPOSE

Deep learning reconstruction (DLR) has been recommended as useful for improving image quality. Moreover, compressed sensing (CS) or DLR has been proposed as useful for improving temporal resolution and image quality on MR sequences in different body fields. However, there have been no reports regarding the utility of DLR for image quality and T-factor assessment improvements on T2-weighted imaging (T2WI), short inversion time (TI) inversion recovery (STIR) imaging, and unenhanced- and contrast-enhanced (CE) 3D fast spoiled gradient echo (GRE) imaging with and without CS in comparison with thin-section multidetector-row CT (MDCT) for non-small cell lung cancer (NSCLC) patients. The purpose of this study was to determine the utility of DLR for improving image quality and the appropriate sequence for T-category assessment for NSCLC patients.

METHODS

As subjects for this study, 213 pathologically diagnosed NSCLC patients who underwent thin-section MDCT and MR imaging as well as T-factor diagnosis were retrospectively enrolled. SNR of each tumor was calculated and compared by paired t-test for each sequence with and without DLR. T-factor for each patient was assessed with thin-section MDCT and all MR sequences, and the accuracy for T-factor diagnosis was compared among all sequences and thin-section CT by means of McNemar's test.

RESULTS

SNRs of T2WI, STIR imaging, unenhanced thin-section Quick 3D imaging, and CE-thin-section Quick 3D imaging with DLR were significantly higher than SNRs of those without DLR (P < 0.05). Diagnostic accuracy of STIR imaging and CE-thick- or thin-section Quick 3D imaging was significantly higher than that of thin-section CT, T2WI, and unenhanced thick- or thin-section Quick 3D imaging (P < 0.05).

CONCLUSION

DLR is thus considered useful for image quality improvement on MR imaging. STIR imaging and CE-Quick 3D imaging with or without CS were validated as appropriate MR sequences for T-factor evaluation in NSCLC patients.

18F-FDG positron emission tomography in oncology: main indications

The development of molecular and functional imaging with new imaging techniques such as computed tomography, magnetic resonance imaging, and positron emission tomography (PET) among others, has greatly improved the detection of tumors, tumor staging, and the detection of possible recurrences. Furthermore, the combination of these different imaging modalities and the continual development of radiotracers for PET have advanced our understanding and knowledge of the different pathophysiological processes in cancer, thereby helping to make treatment more efficacious, improving patients' quality of life, and increasing survival. PET is one of the imaging techniques that has attracted the most interest in recent years for its diagnostic capabilities. Its ability to anatomically locate pathologic foci of metabolic activity has revolutionized the detection and staging of many tumors, exponentially broadening its potential indications not only in oncology but also in other fields such as cardiology, neurology, and inflammatory and infectious diseases.

Diagnosis of recurrence and assessment of post-recurrence survival in patients with extracranial non-small cell lung cancer evaluated by 18F-FDG PET/CT

The accurate diagnosis of recurrence of non small cell lung cancer (NSCLC) is crucial for the appropriate management of patients with suspicion of recurrence (SOR). We evaluated prospectively in the clinical setting the contribution of FDG PET/CT in patients with SOR of NSCLC in terms of sensitivity, specificity, impact on therapy and on survival.

METHODS

Of the 55 patients included in the study, recurrence was confirmed in 37 but, follow up data for survival evaluation was available in 34. There were 59 SOR in the 55 patients and in 41 recurrence was confirmed. 53 of the 59 suspicions, had a contrast enhanced CT. All patients had a FDG PET/CT scan after iv injection of 8 MBq/kg of F18-FDG.

RESULTS

Of the 59 SOR, FDG PET/CT was positive in all 41 in which recurrence was confirmed (100% sensitivity) and, it was negative in 15 of the 18 in which it was ruled out (specificity 83%). In 27 SOR with inconclusive CT, FDG PET/CT showed 100% sensitivity (18/18) and 78% specificity (7/9). FDG PET/CT had an impact on treatment in 42 of the 59 SOR. In all 34 patients, FDG PET/CT diagnosed recurrence and overall survival at 20 months and 5 years was 44% and 11%, respectively. When the extent of recurrence assessed by FDG PET/CT was considered, survival at 20 months and at 5 years of patients with loco-regional recurrence was 77% and 28% and in patients with distant recurrence 14% and 0% (p < 0.001).

CONCLUSION

Despite the small number of patients, our study demonstrates that FDG PET/CT is highly accurate for the detection of NSCLC recurrence. Therefore it has a great impact on the therapy regimen and on survival depending on the extent of the recurrent disease, survival being better for patients with local recurrence. By differentiating local from distant recurrence, it allows the selection of patients who, could potentially benefit from new therapies. The results also suggest that there are grounds to include FDG PET/CT in the guidelines for surveillance for NSCLC.

Partnerships in oncology and radiology: the role of radiology in the detection, staging, and follow-up of lung cancer

In this review, I examine the multifaceted role of radiology in the diagnosis, staging, and management of lung cancer, highlighting new applications and modalities such as computer-aided detection of lung nodules and positron emission tomography/computed tomography for staging and monitoring response to therapy. Lung cancer screening is also discussed.

PET/CT Imaging of Lung Cancer

Fluoro-deoxyglucose positron emission tomography (PET) imaging has a diagnostic and prognostic value in the initial staging, restaging, and surveillance of non-small-cell lung cancer (NSCLC). When used in conjunction with conventional radiologic imaging, PET imaging has been shown to result in significant changes in clinical management of NSCLC. Specifically, baseline PET imaging can improve initial staging and guide surgical and radiotherapy planning, whereas repeat PET imaging after the initiation of chemoradiotherapy can predict tumor response and help tailor therapy. After the end of definitive treatment, PET has greater diagnostic accuracy than other imaging modalities for the detection of tumor recurrence. The recent development of fused PET/CT imaging has improved the radiologic evaluation of NSCLC patients by combining metabolic and anatomic imaging; however, this has resulted in more complexity in the image interpretation. It is important for the interpreting physician to understand the role PET/CT plays in the staging, assessment of treatment, and follow-up after therapy in the multidisciplinary management of patients with NSCLC.